1. Burke C, Fulda G, Castella J. Neuroleptic malignant syndrome in a trauma patient. J Trauma. 1995;39: 796-798.
2.
2. Caroff S, Mann S. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-200.
3.
3. Blair D, Dauner A. Nonneuroleptic etiology of extrapyramidal symptoms. Clin Nurs Spec. 1993;7:225-231.
4.
4. Rosenberg M, Green M. Neuroleptic malignant syndrome: a review of response to therapy. Arch Intern Med. 1989;149:1927-1927.
5.
5. Fowler S, Hertzog J, Wagner B. Pharmacological interventions for agitation in head injured patients in the acute care setting. J Neurosci Nurs. 1995;27:119-123.
6.
6. Heird S. Rhoads J. Neuroleptic malignant syndrome in a trauma patient: case report. J Trauma. 1989;29:1595-1597.
7.
7. Teicher M, Baldessarini R. Developmental pharmacodynamics. In: Popper C, ed. Psychiatric Pharmacosciences of Children and Adolescents. Washington, DC: American Psychiatric Press; 1987:45-80.
8.
8. Fujii N. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatrica Scand. 1994;90:424-426.
9.
9. Sakkas P.Davis J, Hua J. et al. Pharmacotherapy of neuroleptic malignant syndrome. Psychiatric Ann. 1991;21: 157-164.
10.
10. Sakkas P, Davis JJanicak P, et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27:381-384.
